Immune cells take on brain tumors in new pilot study
NCT ID NCT05640193
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 26 times
Summary
This early-phase trial tests a treatment called lifileucel (LN-144) for people with melanoma that has spread to the brain and is no longer responding to standard immunotherapy. The treatment uses a patient's own immune cells, called tumor-infiltrating lymphocytes (TILs), which are grown in a lab and then infused back into the patient. The study aims to see if this approach is feasible and safe for 10 participants with asymptomatic brain metastases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.